AstraZeneca’s (AZN) Sell Rating Reaffirmed at Goldman Sachs Group

AstraZeneca (NYSE:AZN)‘s stock had its “sell” rating reiterated by research analysts at Goldman Sachs Group in a research note issued on Friday.

Other analysts also recently issued reports about the stock. ValuEngine raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research report on Saturday, July 28th. Guggenheim assumed coverage on shares of AstraZeneca in a research report on Monday, October 8th. They issued a “buy” rating on the stock. Wolfe Research assumed coverage on shares of AstraZeneca in a research report on Tuesday, October 23rd. They issued an “outperform” rating on the stock. Zacks Investment Research downgraded shares of AstraZeneca from a “buy” rating to a “hold” rating in a research report on Tuesday, October 16th. Finally, Jefferies Financial Group downgraded shares of AstraZeneca from a “buy” rating to a “hold” rating in a research report on Thursday, August 16th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $40.34.

NYSE AZN traded down $0.73 during trading on Friday, hitting $40.67. The company had a trading volume of 7,069,209 shares, compared to its average volume of 4,088,519. The company has a current ratio of 0.86, a quick ratio of 0.66 and a debt-to-equity ratio of 1.36. AstraZeneca has a one year low of $31.99 and a one year high of $41.78. The firm has a market capitalization of $105.09 billion, a PE ratio of 9.50, a price-to-earnings-growth ratio of 2.13 and a beta of 0.57.

AstraZeneca (NYSE:AZN) last issued its quarterly earnings data on Thursday, November 8th. The company reported $0.71 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.33 by $0.38. AstraZeneca had a net margin of 11.29% and a return on equity of 27.32%. The business had revenue of $5.34 billion during the quarter, compared to analyst estimates of $5.26 billion. During the same period in the prior year, the business earned $1.12 EPS. The company’s revenue for the quarter was down 14.3% on a year-over-year basis. On average, sell-side analysts predict that AstraZeneca will post 1.68 earnings per share for the current year.

In other AstraZeneca news, major shareholder Plc Astrazeneca bought 600,000 shares of AstraZeneca stock in a transaction dated Monday, October 22nd. The shares were purchased at an average cost of $5.00 per share, with a total value of $3,000,000.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

Several large investors have recently added to or reduced their stakes in AZN. Factorial Partners LLC purchased a new stake in AstraZeneca during the 3rd quarter valued at about $119,000. Bessemer Group Inc. grew its position in AstraZeneca by 64.3% during the 2nd quarter. Bessemer Group Inc. now owns 4,651 shares of the company’s stock valued at $163,000 after purchasing an additional 1,820 shares during the last quarter. NEXT Financial Group Inc purchased a new stake in AstraZeneca during the 3rd quarter valued at about $169,000. FNY Investment Advisers LLC purchased a new stake in AstraZeneca during the 2nd quarter valued at about $175,000. Finally, Tiverton Asset Management LLC purchased a new stake in AstraZeneca during the 2nd quarter valued at about $178,000. 16.03% of the stock is currently owned by hedge funds and other institutional investors.

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

See Also: What are Institutional Investors?

Analyst Recommendations for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply